LQDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Liquidia Corp (LQDA) does not present a strong buy opportunity at this moment for a beginner investor with a long-term strategy. While the company shows promising growth in revenue and has positive analyst sentiment, insider selling, technical indicators showing no clear upward momentum, and lack of strong proprietary trading signals suggest waiting for a better entry point.
The MACD histogram is negative (-0.247) and expanding downward, indicating bearish momentum. RSI is neutral at 44.568, and moving averages are converging, showing no clear trend. Current price is below the pivot level of 38.784, with support at 36.416 and resistance at 41.153.
Analysts have raised price targets significantly, with Wells Fargo increasing to $51 and H.C. Wainwright to $55, citing strong market potential and impressive financial performance.
Yutrepia's annualized sales of $360.4M in Q4 2025 and the development of L606 in pivotal studies highlight strong product pipeline and growth potential.
Insider selling has increased by 135.92% in the last month, with the CEO indirectly selling 53,300 shares, raising concerns about management's confidence.
Technical indicators do not show clear upward momentum, and the stock has a 60% chance of a minor 1.59% gain in the next day but a potential -2.15% decline in the next month.
In Q4 2025, revenue increased significantly by 3054.65% YoY to $92.02M, driven by Yutrepia's sales. However, net income dropped by -140.13% YoY to $14.55M, and EPS fell by -139.53% YoY to $0.17. Gross margin improved to 92.33%, up 72.32% YoY, indicating strong operational efficiency.
Analysts are generally positive on LQDA. Wells Fargo and H.C. Wainwright maintain Overweight and Buy ratings, respectively, with increased price targets. However, Oppenheimer remains cautious with an Underperform rating, citing concerns about product differentiation despite strong sales performance.
